MG
AVNS

Michael Gelband’s Avanos Medical AVNS Stock Holding History

Michael Gelband’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-421,504
Closed -$5.91M – 1572
2026
Q1 		$5.91M Sell
421,504
-164,981
-28% -$2.22M 0.05% 387
2025
Q4 		$6.59M Buy
586,485
+222,292
+61% +$2.54M 0.05% 381
2025
Q3 		$4.21M Sell
364,193
-883,744
-71% -$10.3M 0.04% 473
2025
Q2 		$15.3M Buy
1,247,937
+1,217,519
+4,003% +$15.3M 0.13% 147
2025
Q1 		$436K Buy
+30,418
New +$475K ﹤0.01% 1140
2024
Q3 		– Sell
-59,642
Closed -$1.19M – 1614
2024
Q2 		$1.19M Buy
59,642
+22,428
+60% +$437K 0.01% 963
2024
Q1 		$741K Buy
+37,214
New +$719K 0.01% 1038
2023
Q4 		– Sell
-93,976
Closed -$1.9M – 1468
2023
Q3 		$1.9M Buy
93,976
+42,000
+81% +$952K 0.02% 687
2023
Q2 		$1.33M Buy
51,976
+44,499
+595% +$1.17M 0.01% 988
2023
Q1 		$222K Buy
+7,477
New +$217K ﹤0.01% 1553
2022
Q2 		– Sell
-21,428
Closed -$718K – 1924
2022
Q1 		$718K Buy
21,428
+12,212
+133% +$393K 0.01% 1339
2021
Q4 		$320K Sell
9,216
-19,418
-68% -$628K ﹤0.01% 1636
2021
Q3 		$893K Sell
28,634
-48,526
-63% -$1.65M 0.01% 1076
2021
Q2 		$2.81M Buy
77,160
+55,276
+253% +$2.29M 0.03% 541
2021
Q1 		$957K Sell
21,884
-44,596
-67% -$2.09M 0.01% 942
2020
Q4 		$3.05M Sell
66,480
-51,657
-44% -$2.15M 0.03% 395
2020
Q3 		$3.92M Buy
118,137
+22,559
+24% +$721K 0.08% 220
2020
Q2 		$2.81M Buy
95,578
+75,879
+385% +$2.2M 0.07% 309
2020
Q1 		$530K Buy
+19,699
New +$588K 0.03% 466

Other funds holding AVNS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Michael Gelband's AVNS Position: Q2 2026 in Review

Michael Gelband sold out of Avanos Medical (AVNS) in Q2 2026, closing a stake of 421,504 shares — an estimated $5.91M sold.

Michael Gelband first reported a position in AVNS in Q1 2020 and held it in 19 quarters. The position peaked at $15.3M in Q2 2025. 284 funds tracked by Wall St. Rank hold AVNS as of Q2 2026.

  • Michael Gelband reported no remaining Avanos Medical position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 421,504 Avanos Medical shares in Q2 2026, an estimated $5.91M.
  • Michael Gelband first reported a position in Avanos Medical in Q1 2020 and held it in 19 quarters.
  • Michael Gelband's Avanos Medical position peaked at $15.3M in Q2 2025.
  • 284 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.